5-MeO-DMT: Compound Guide

Urgent first. If someone has seizures, chest pain, trouble breathing or severe confusion after any psychoactive substance, call 911 or US Poison Help at 1-800-222-1222. For a mental health crisis in the US, call or text 988.

This page is education only. It gives no amounts, no collection, extraction or preparation information and no sourcing advice. Evidence labels: promising but limited, insufficient evidence, preclinical (cells/animals only).

What 5-MeO-DMT is

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring, short-acting psychedelic tryptamine produced by a variety of plant and animal species. A narrative review found it is a serotonin agonist with highest affinity for 5-HT1A receptors. [1] That differs from DMT, which reviews describe as acting at 5-HT1A, 5-HT2A and 5-HT2C receptors. [2] It is a different compound from DMT and is listed separately in US law. See DMT and DMT vs 5-MeO-DMT. Do not confuse it with the Amazonian brew ayahuasca (ayahuasca).

Natural sources and sourcing concerns

Plants containing 5-MeO-DMT have been used for ritual and spiritual purposes throughout history, according to the 2022 review. [1] Among animals, the Sonoran Desert toad (Incilius alvarius, also called the Colorado River toad) is the only animal known to secrete 5-MeO-DMT as a chemical defense; where the toad gets it is not known, and a 2025 field study found diet is not directly linked to production. [3] A forensic analysis of secretion samples from toads in Arizona found 5-MeO-DMT as the main tryptamine alongside several related compounds, with relatively high variability between samples for some of them. [4] We do not give figures, because one study's samples do not describe any product.

"Toad venom" products raise animal-welfare and conservation questions and legal ones; the topic is covered, without collection instructions, at animal-derived sources and sourcing concerns. An isolated or synthetic compound is also not a cultural practice; see traditional preparations vs isolated compounds.

What research shows

Human research is early and small.

• Safety, early trials: promising but limited. A systematic review of three phase I and I/II trials (78 participants, two in healthy volunteers and one in treatment-resistant depression) found no serious adverse events and no dropouts, while calling for larger randomized trials with follow-up. [5]
• Repeated low-amount formulation. A phase I randomized, double-blind placebo-controlled trial of a sublingual formulation in adults with moderate depression and/or anxiety symptoms found it well tolerated, with mild nausea and headache. It tested safety and tolerability, not benefit. [6]
• Efficacy: insufficient evidence. The 2022 review concluded that clinical studies with humans were lacking and that further clinical exploration was warranted, with the precautions used for other classic psychedelics. [1] Most reports of benefit come from surveys of people who chose to use it, which cannot show cause.
• Mechanism hypothesis, not a finding. One 2025 review proposes that 5-MeO-DMT effects may resemble epileptiform activity and describes "reactivations", the sudden re-experiencing of drug effects, as common afterward but not after typical psychedelics. It is a hypothesis. [7]
• Animal data exist (for example in mice) but are not evidence for people.

Risks

• Reviews describe profound alterations in consciousness, including mystical-type experiences. [1] Short-term safety in trials was good, but long-term adverse events have not been assessed. [5]
• The reactivation phenomenon above, and possible links to seizure-like activity, are reported but not well studied. [7]
• A meta-analysis of classic psychedelic trials, including 5-MeO-DMT, found serious adverse events in about 4% of participants with preexisting neuropsychiatric disorders. [8]
• Interaction evidence is thin: a systematic review found only 2 human studies on 5-MeO-DMT interactions. [9]
• Pregnancy: a scoping review of human pregnancy outcomes did not list 5-MeO-DMT among the substances with eligible studies, and says absence of data is not evidence of safety. [10]

Legal status

Not legal advice; laws change. In the United States, 5-methoxy-N,N-dimethyltryptamine is listed in Schedule I of 21 CFR 1308.11 (eCFR, read 2026-10-22). [11] Other countries: not verified; wildlife laws on the toad were not read. See psychedelic legal status.